Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Methods in Cell Biology|March 28, 2024
Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccineEmily Nickles, Runze Xia, Rui Sun, et al.Journal of Leukocyte Biology|March 14, 2015
Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulationZhe Shao, Zulkarnain Harfuddin, Wan Lu Pang, et al.Cancer Immunology, Immunotherapy : CII|March 7, 2018
CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotypeBhushan Dharmadhikari, Emily Nickles, Zulkarnain Harfuddin, et al.Oncoimmunology|May 4, 2016
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responsesBhushan Dharmadhikari, Meihui Wu, Nur Sharalyn Abdullah, et al.Oncoimmunology|December 24, 2024
Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137Rui Sun, Kang Yi Lee, Yu Mei, et al.The Journal of Biological Chemistry|January 11, 2020
CD137 negatively affects "browning" of white adipose tissue during cold exposureRaj Kamal Srivastava, Annalena Moliner, Ee-Soo Lee, et al.Theranostics|December 2, 2025
Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatmentKang Yi Lee, Heng Sun, Yu Mei, et al.Cancer Immunology, Immunotherapy : CII|October 18, 2021
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefitEmily Nickles, Bhushan Dharmadhikari, Li Yating, et al.Pageof 1